

## Lipidor adds 1.1 MSEK through sale of shares in associated company and agreement of loan

**STOCKHOLM, Sweden, 21st December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that 63 shares, corresponding to approximately 0.5 MSEK, have been sold in the associated company Emollivet, and that a loan of approximately 0.6 MSEK has been taken up from the company's largest owner, Cerbios-Pharma SA.**

In 2023, Lipidor has made a phased divestment of its holding in the associated company Emollivet and today another transaction is announced. A total of 63 shares in Emollivet have been sold to Cerbios-Pharma SA at a price per share of SEK 7,290. The price has been determined through an external valuation of Emollivet carried out by independent advisors. Through the transaction, Lipidor will receive approximately 0.5 MSEK and after the transaction, Lipidor will continue to own 253 shares in Emollivet.

An interest-free loan of approximately 0.6 MSEK has also been raised from the company's largest shareholder Cerbios-Pharma SA and repayment is made with Emollivet shares. The loan matures on 1 March 2024. The size of the loan corresponds to 89 shares at a price of SEK 7,290 per share.

The plan is also to find a taker for the remaining ownership in Emollivet and to work towards the possibility of using IP linked to the animal segment for additional bridge financing.

*This information is information that Lipidor AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-12-21 10:45 CET.*

### **For more information, please contact:**

Ola Holmlund, CEO

Telephone: +46 (0) 72 50 70 369

Email: [ola.holmlund@lipidor.se](mailto:ola.holmlund@lipidor.se)

The company's Certified Adviser is Carnegie Investment Bank AB (publ).

### **About Lipidor AB**

Lipidor AB (Nasdaq First North Growth Market: LIPI) ([www.lipidor.se](http://www.lipidor.se)) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor's priority project is AKP02G2, which focusses on psoriasis.

**Attachments**

**Lipidor adds 1.1 MSEK through sale of shares in associated company and agreement of loan**